"Designing Growth Strategies is in our DNA"
Bacteremia is characterized by the presence of bacteria on an individual’s blood. Bacteremia can be caused by factors like an indwelling catheter, surgery, tissue wound among others. The infection can be short-termed or can lead to serious complications like sepsis or septic shock if not treated properly. Bacteremia can cause chronic diseases such as meningitis or pneumonia. Certain patients having HIV, diabetes mellitus, undergoing organ transplant and chronic hemodialysis are more susceptible to acquiring bacteremia.
Bacteremia is predominantly treated by antibiotics that target the infection-causing bacteria. Patients that are undergoing surgery or catheterization are pre immunized against bacteremia by antibiotics. Majority of the antibiotics prescribed are generic in nature.
Several research institutes along with pharmaceutical companies have been concentrating on studying and developing novel treatment options for bacteremia as the incidences of antibiotic-resistant bacterial infection is on the rise. For instance; ETX2514, which is being studied by Entasis Therapeutics, Inc., is currently in phase-3 clinical trials for the evaluation of efficacy and safety of ETX2514 in patients infected with Acinetobacter Baumannii-calcoaceticus Complex
To know how our report can help streamline your business, Speak to Analyst
As of 2019, approximately 61% of a clinical trial in bacteremia is in Phase 3 and Phase 4 stage. Majority of these clinical studies are carried out by research institutions.
The report on ‘Bacteraemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bacteraemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bacteraemia.
The report on ‘Bacteraemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.